WebApr 4, 2024 · Eligible patients with previously untreated metastatic nonsquamous non–small-cell lung cancer without EGFR/ALK alterations were randomly assigned 2:1 to pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles with pemetrexed and investigator's choice of carboplatin/cisplatin for four cycles, followed by … WebConclusion: Pemetrexed plus platinum doublet regimen is an efficacious treatment for advanced nonsquamous NSCLC patients. Our findings support the use of pemetrexed plus platinum doublet regimen as first-line treatment in advanced nonsquamous NSCLC patients because of its potential survival benefits.
NON-SMALL CELL LUNG CANCER TREATMENT …
WebNSCLC indicates non–small cell lung cancer. aThese ineligible patients received study treatment and so were included in the safety analysis. Figure 2. Kaplan-Meier Plots for Overall Survival and Progression-Free Survival in … Web2.1 Recommended Dosage for Non-Squamous NSCLC. The recommended dose of Pemetrexed for Injection when administered with cisplatin for initial treatment of locally … hire for a night
Efficacy of pemetrexed-based regimens in advanced non–small …
WebPlatinum compounds, e.g., cisplatin and carboplatin, have been used for the treatment of non-small cell lung cancer (NSCLC) and breast cancer in the clinic for decades. Cisplatin causes DNA damage and forms irreversible adducts with DNA, causing damage to replication and transcription processes [ 22 ]. WebApr 3, 2024 · 1.1 Non-Squamous Non-Small Cell Lung Cancer (Nsclc) Pemetrexed for injection is indicated: ... Among the 226 patients who received cisplatin with … WebDec 1, 2024 · Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial - PMC Back to Top Skip to main content An official website of the United States government homes for sale near omaha ne